Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids  Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

Similar presentations


Presentation on theme: "Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids  Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,"— Presentation transcript:

1 Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids 
Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD, Heleen Scheerens, PhD, Joseph R. Arron, MD, PhD, Yanan Zheng, PhD, Wendy S. Putnam, PhD, Merdad V. Parsey, MD, PhD, Sean P. Bohen, MD, PhD, John G. Matthews, MB, BS, PhD  Journal of Allergy and Clinical Immunology  Volume 132, Issue 3, Pages e12 (September 2013) DOI: /j.jaci Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Patient disposition.
Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Percentage change in FEV1 from baseline to week 20: (A) mITT; (B) periostin-high patients; and (C) periostin-low patients. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Kaplan–Meier plots of time to treatment failure: (A) mITT; (B) periostin-high patients; and (C) periostin-low patients. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E1 Percentage change in PEF from baseline to week 20: (A) mITT; (B) periostin-high patients; and (C) periostin-low patients. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E2 Median values of pharmacodynamic biomarkers during the study.
Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E3 Median change from baseline of pharmacodynamic biomarkers after treatment. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Download ppt "Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids  Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,"

Similar presentations


Ads by Google